Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global VC OrbiMed Leads Series A Financing In Its Second China Start-up Investment

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Life sciences and health investment firm OrbiMed announced March 8 that it has led $6.6 million series A financing for Chinese dental company EA Inc., which is focusing on providing invisible orthodontic braces to China's rising middle class
Advertisement

Related Content

OrbiMed Invests $8 Million In Response Biomedical To Reap Rewards Of China's Rapid Growth POCT Market
OrbiMed Invests $8 Million In Response Biomedical To Reap Rewards Of China's Rapid Growth POCT Market
With Investment In Bharat Serum, OrbiMed Speeds Up Its Second Deal In India In Four Months
With Investment In Bharat Serum, OrbiMed Speeds Up Its Second Deal In India In Four Months
Astellas Takes Hostile $3.5 Bil. Bid To OSI Shareholders
The Year Of The Tiger Looking Strong For IPOs In China Following Sinopharm Success
Novartis Korea Venture Fund, OrbiMed Co-lead Series A Financing For South Korean mAb Developer PharmAbcine
Novartis Korea Venture Fund, OrbiMed Co-lead Series A Financing For South Korean mAb Developer PharmAbcine
Advertisement
UsernamePublicRestriction

Register

SC074482

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel